{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:30Z","timestamp":1787070870867,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      The objective was to evaluate the diagnostic performance of surveillance\n                      <jats:sup>11<\/jats:sup>\n                      C-choline positron emission tomography\/computed tomography (PET\/CT) for the detection of disease relapse in patients with a history of biochemically recurrent (BCR) prostate cancer (PCa) and prostate-specific antigen (PSA) \u22640.1 ng\/ml.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      We included patients who had been treated for BCR PCa and had a surveillance\n                      <jats:sup>11<\/jats:sup>\n                      C-choline PET\/CT at serum PSA \u22640.1 ng\/ml. Positive surveillance PET\/CT was defined as a study that identified a new tracer-avid lesion or new tracer uptake in a previously treated lesion or both. Findings were confirmed against a composite radiologic-pathologic gold standard. Time to recurrence association analyses were performed for disease relapse risk with the use of Cox proportional hazards regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 13 (12.1%) of the 107 patients had positive surveillance PET\/CT scans, confirmed on pathologic assessment (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5) and subsequent imaging (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 8). Among these 13 patients, ten had distant metastases, two had local recurrence, and one had both. Nine of the ten patients with metastases had oligometastatic disease defined as the presence of \u22643 metastases. Serum PSA became detectable again in only seven patients with positive surveillance PET\/CT, after a mean interval from surveillance PET\/CT of 292 days (range: 105\u2013543 days). We identified an association of N stage with increased risk of recurrence (hazard ratio = 3.85;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.036) although this was not significant after accounting for multiple testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Surveillance i\n                      <jats:sup>11<\/jats:sup>\n                      C-choline PET\/CT can detect early disease relapse at serum PSA \u22640.1 ng\/ml in patients with a history of BCR PCa.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_373_19","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T10:18:40Z","timestamp":1599646720000},"page":"358-365","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["11C-choline positron emission tomography\/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen \u22640.1 ng\/ml"],"prefix":"10.4103","volume":"17","author":[{"given":"Ishan","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann T.","family":"Packard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene D.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas B.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimki","family":"Haloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindie L.","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit H.","family":"Goenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20241021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0302-2838(02)00505-5","article-title":"PSA progression following radical prostatectomy and radiation therapy: New standards in the new Millennium","volume":"43","author":"Djavan","year":"2003","journal-title":"Eur Urol"},{"key":"R2-9-20241021","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.rcl.2012.08.005","article-title":"Imaging of recurrent prostate cancer","volume":"50","author":"F\u00fctterer","year":"2012","journal-title":"Radiol Clin North Am"},{"key":"R3-9-20241021","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-9-20241021","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0090-4295(03)00404-7","article-title":"Long-term cancer control of radical prostatectomy in men younger than 50 years of age: Update 2003","volume":"62","author":"Khan","year":"2003","journal-title":"Urology"},{"key":"R5-9-20241021","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1007\/s00259-014-2872-x","article-title":"Impact of 11C-choline PET\/CT on clinical decision making in recurrent prostate cancer: Results from a retrospective two-centre trial","volume":"41","author":"Ceci","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-9-20241021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-015-3202-7","article-title":"PET\/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: Meta-analysis and critical review of available data","volume":"43","author":"Fanti","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-9-20241021","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jcb.10659","article-title":"Choline phospholipid metabolism: A target in cancer cells?","volume":"90","author":"Ackerstaff","year":"2003","journal-title":"J Cell Biochem"},{"key":"R8-9-20241021","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.2967\/jnumed.114.138313","article-title":"Early biochemical relapse after radical prostatectomy: Which prostate cancer patients may benefit from a restaging 11C-choline PET\/CT scan before salvage radiation therapy?","volume":"55","author":"Castellucci","year":"2014","journal-title":"J Nucl Med"},{"key":"R9-9-20241021","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00259-007-0581-4","article-title":"The detection rate of [11C]choline-PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer","volume":"35","author":"Krause","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-9-20241021","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.juro.2012.10.069","article-title":"Operational characteristics of (11)c-choline positron emission tomography\/computerized tomography for prostate cancer with biochemical recurrence after initial treatment","volume":"189","author":"Mitchell","year":"2013","journal-title":"J Urol"},{"key":"R11-9-20241021","first-page":"1270","article-title":"(11)C-choline PET\/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients","volume":"41","author":"Picchio","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-9-20241021","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00259-017-3700-x","article-title":"PET and PET\/CT with radiolabeled choline in prostate cancer: A critical reappraisal of 20 years of clinical studies","volume":"44","author":"Giovacchini","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-9-20241021","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"R14-9-20241021","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/pcan.2016.71","article-title":"Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: Post hoc analysis of PREVAIL","volume":"20","author":"Bryce","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R15-9-20241021","first-page":"156","article-title":"Contribution of 11C-choline PET\/CT in prostate carcinoma biochemical relapse with serum PSA level below 1 ng\/ml","volume":"37","author":"G\u00f3mez-de la Fuente","year":"2018","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"R16-9-20241021","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00259-018-4253-3","article-title":"11C-choline PET\/CT predicts survival in prostate cancer patients with PSA & lt;1 NG\/ml","volume":"46","author":"Giovacchini","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R17-9-20241021","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00259-015-3177-4","article-title":"(11)C-choline PET\/CT in castration-resistant prostate cancer patients treated with docetaxel","volume":"43","author":"Ceci","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-9-20241021","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrurol.2014.21","article-title":"Small cell carcinoma of the prostate","volume":"11","author":"Nadal","year":"2014","journal-title":"Nat Rev Urol"},{"key":"R19-9-20241021","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","article-title":"Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European expert consensus panel","volume":"50","author":"Fitzpatrick","year":"2014","journal-title":"Eur J Cancer"},{"key":"R20-9-20241021","doi-asserted-by":"crossref","first-page":"472","DOI":"10.21037\/tau.2018.05.10","article-title":"Surrogate endpoints in early prostate cancer research","volume":"7","author":"Williams","year":"2018","journal-title":"Transl Androl Urol"},{"key":"R21-9-20241021","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2967\/jnumed.113.123018","article-title":"Detection of recurrent prostate cancer after radical prostatectomy: Comparison of 11C-choline PET\/CT with pelvic multiparametric MR imaging with endorectal coil","volume":"55","author":"Kitajima","year":"2014","journal-title":"J Nucl Med"},{"key":"R22-9-20241021","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68) Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-9-20241021","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"key":"R24-9-20241021","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","article-title":"Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET\/CT","volume":"44","author":"Schwenck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-9-20241021","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2017.07.011","article-title":"Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease","volume":"8","author":"Evans","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"R26-9-20241021","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00259-011-2030-7","article-title":"Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET\/CT detection rate in patients with rising PSA after radical prostatectomy","volume":"39","author":"Schillaci","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_373_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:58Z","timestamp":1787067478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_373_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_373_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}